(주)지아이이노베이션

SITC 2024_CAR-T 포스터

GI-101A, a Novel CD80-IgG4-IL2v2 Fusion Protein, Promotes CAR-T Expansion and Enhances Anticancer Potential by Increasing Memory T Cell Population in a Lymphoma Model
ASCO 2024_GI-102 포스터

A first-in-human, phase 1/2a study of GI-102 (CD80-IL2v3) in patients with advanced or metastatic solid tumors: Initial results from dose escalation.
SITC 2023_GI-102 포스터

GI-102, a novel CD80-IgG4-IL2v3 fusion protein driving lymphocytes expansion and anti-cancer potential through regulation of immune cells in the tumor microenvironment
2023 SITC_GI-108 포스터

GI-108, a novel anti-CD73-IL2v bispecific fusion protein augments anti-tumor immunity by alleviating immunosuppressive adenosine pathway in CD8+ T cells
SITC 2023_Keynote-B59 포스터

Keynote-B59: Dose escalation of a phase 1/2 first-in-human, open-label study of GI-101, a novel immunocytokine combining CD80-IL2v, in combination with pembrolizumab in advanced solid tumors
SITC 2023_GI-102 포스터

A first-in-human, open-label, multicenter, phase 1/2a, dose escalation and expansion study of GI-102, a novel immunocytokine combining CD80-IL2v3, in patients with advanced or metastatic solid tumors
ESMO 2023 포스터

Population Pharmacokinetic-Pharmacodynamic Modeling to Inform Optimal Dosing Strategies for GI-101, a Novel Fusion Protein, Targeting IL2βγR and CTLA4
ESMO 2023 포스터

An open-label, multicenter, phase 1/2 study of GI-101, CD80-IgG4 Fc-IL2v, in advanced solid tumors(Part A of GII-101-P101; KEYNOTE-B59)
SITC 2022 포스터

Preliminary results of GII-101-P101 (Keynote-B59): GI-101 (CD80-IgG4 Fc-IL2v) as a single agent and in combination with pembrolizumab in patients with advanced and/or metastatic solid tumors
SITC 2021 포스터

A phase 1/2, open-label, dose escalation and expansion study of GI-101 as a single agent and in combination with a Pembrolizumab, Lenvatinib or Local RT in advanced solud tumors (KEYNOTE-B59)

개인정보의 수집·이용 목적	회사에 관한 최신 뉴스 및 홍보 정보 제공
수집·이용할 개인정보 항목	[필수항목] 이름, 이메일주소
보유 및 이용 기간	구독 해지시까지

COMPANY

개인정보 수집·이용 동의